Skip to content
Company Analysis

PDS Biotechnology Corporation PDSB

A comprehensive view of key metrics, scores, and financial health for PDS Biotechnology Corporation

Overview of PDS Biotechnology Corporation

PDSB NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
PDS Biotechnology Corporation (PDSB), is a Micro Cap company, in the Biotechnology industry, last closed at $1.52, about 0.0% overvalued vs fair value, +62.6% 1Y return, ranked 1123/1145 in sector.
Metrics ROE -244.2%
USD 1.52
16.92%
(Delayed)
• Vol 90d: 260.5%
52-Week Range
Market Cap
$110.16M
Enterprise Value
$108.89M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Valuation
Fair
Growth
Weak
Profitability
Fair
Health
Fair
Valuation
Fair
Completeness: 62%
Confidence: 73%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.pdsbiotech.com
HQ Princeton, NJ
Employees 24
Fiscal year Dec 31

Next Events

Earnings Nov 12 Estimated

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$26.7M
-35.9%%
Total Revenue
$0
Net Income
-$34.5M
8.3%%
Operating Expense
$31.5M
-13.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
11.6 months
Poor

Critical: Cash runway under 12 months

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating PDS Biotechnology Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
37
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.79), with robust interest coverage.

Key risks

  • ROIC Below WACC or Peers ROIC at 27.3th percentile suggests inefficient capital deployment.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 60% Coverage
Trade-Off Triangle Visualization A ternary plot showing PDSB's balance between Growth (51.6%), Profitability (22.6%), and Safety (25.8%). Growth 52% Safety 26% Profitability 23%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

76th percentile vs peers
76
Key Signals
TSR 63.0% 76p
Strengths
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

37th percentile vs peers
38
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for PDS Biotechnology Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000